Diabetes is a chronic illness that develops when the pancreas either produces insufficient amounts of insulin or when the body cannot properly utilize the insulin that it does
Based on current trial populations and how the FDA has handled semaglutide and tirzepatide approvals, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, OSA) Adults 18 and older Not pregnant or breastfeeding No history of MTC or MEN 2 Retatrutide will almost certainly launch at a high price point estimates suggest $1,200$1,500 per month at list price
Injection site reactions Redness, itching, swelling, and minor bruising occur in approximately 1.4% of semaglutide users and 2.4% of tirzepatide users
These medications can be associated with significant ocular complications, according to a new clinical report by the AOAs Evidence-based Optometry Committee